{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:58:36Z","timestamp":1788026316724,"version":"build-2784847793"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Jiangsu Hengrui Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective topical therapies for mild-to-moderate atopic dermatitis (AD) should provide rapid itch relief, sustained anti-inflammatory efficacy and minimal local toxicity. Existing options, including corticosteroids and calcineurin inhibitors, are limited by long-term adverse effects, highlighting the need for safer, steroid-sparing alternatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of ivarmacitinib ointment, a highly selective topical Janus kinase 1 inhibitor, applied twice daily in adults with mild-to-moderate AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase III evaluation was part of a multicentre randomized double-blind vehicle-controlled seamless adaptive phase II\/III trial conducted at 27 sites in China. Adults aged 18\u201375\u2005years with Hanifin\u2013Rajka-defined mild-to-moderate AD were randomized (1 : 1 : 1) to ivarmacitinib ointment 0.5%, ivarmacitinib ointment 1% or vehicle for 8 weeks. Patients who initially received the vehicle were re-randomized to active treatment for a blinded extension through week 52. Co-primary endpoints were Investigator\u2019s Global Assessment (IGA) response (score 0\/1 with \u2265 2-grade improvement) and \u2265 75% improvement in Eczema Area and Severity Index (EASI 75) at week 8.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 8, significantly more patients achieved an IGA response with ivarmacitinib than with vehicle [ivarmacitinib 0.5%: 21.3% vs. 10.6% (P = 0.02); ivarmacitinib 1%: 26.2% vs. 10.6% (P = 0.001)]. Likewise, EASI 75 responses were higher [ivarmacitinib 0.5%: 42.6% vs. 17.9%; ivarmacitinib 1%: 45.1% vs. 17.9% (both P &amp;lt; 0.001)]. Relief from pruritus was seen within 48\u2005h and maintained through week 52, with sustained improvements in SCORing Atopic Dermatitis (SCORAD), affected body surface area and Dermatology Life Quality Index. During the vehicle-controlled period, treatment-emergent adverse events occurred in 42.6% (n = 52\/122), 56.6% (n = 69\/122) and 52.0% (n = 64\/123) of patients in the ivarmacitinib 0.5%, ivarmacitinib 1% and vehicle groups, respectively; most were mild and infection-related events were infrequent. No treatment-related adverse event occurred in \u2265 2% of patients in the ivarmacitinib 1% or vehicle groups, while in the ivarmacitinib 0.5% group, only folliculitis (n = 5\/122; 4.1%) and increased blood uric acid (n = 4\/122; 3.3%) were reported in \u2265 2% of patients. No skin atrophy, telangiectasia or application-site irritation was observed. Long-term safety through week 52 remained consistent, with no new safety signals noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Twice-daily ivarmacitinib ointment (0.5% or 1%) produced rapid, durable and well-tolerated improvements in the signs, symptoms and itch experienced by adults with mild-to-moderate AD, supporting its potential as a safe, steroid-sparing topical therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf482","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T13:05:34Z","timestamp":1764335134000},"page":"629-639","source":"Crossref","is-referenced-by-count":2,"title":["Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II\/III clinical trial"],"prefix":"10.1093","volume":"194","author":[{"given":"Duoqin","family":"Wang","sequence":"first","affiliation":[{"name":"Huashan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunyi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiande","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-6747","authenticated-orcid":false,"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9104-1294","authenticated-orcid":false,"given":"Jinhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Huashan Hospital, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"2026031913332832200_ljaf482-B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"2026031913332832200_ljaf482-B2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jaci.2022.10.023","article-title":"Novel insights into atopic dermatitis","volume":"151","author":"Schuler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026031913332832200_ljaf482-B3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","article-title":"Guidelines of care for the management of atopic dermatitis in adults with topical therapies","volume":"89","author":"Sidbury","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026031913332832200_ljaf482-B4","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1001\/jama.2016.1459","article-title":"Management of atopic dermatitis","volume":"315","author":"Stein","year":"2016","journal-title":"JAMA"},{"key":"2026031913332832200_ljaf482-B5","first-page":"9678","article-title":"Atopic dermatitis: a brief review of recent advances in its management","volume":"15","author":"Alenazi","year":"2023","journal-title":"Dermatol Reports"},{"key":"2026031913332832200_ljaf482-B6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2026031913332832200_ljaf482-B7","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026031913332832200_ljaf482-B8","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12016-021-08880-3","article-title":"Update on the pathogenesis and therapy of atopic dermatitis","volume":"61","author":"Li","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026031913332832200_ljaf482-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026031913332832200_ljaf482-B10","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031913332832200_ljaf482-B11","doi-asserted-by":"crossref","first-page":"1068260","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"2026031913332832200_ljaf482-B12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/bjd\/ljae342","article-title":"A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council","volume":"192","author":"Haag","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026031913332832200_ljaf482-B13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026031913332832200_ljaf482-B14","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","article-title":"Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study","volume":"85","author":"Nakagawa","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026031913332832200_ljaf482-B15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026031913332832200_ljaf482-B16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026031913332832200_ljaf482-B17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.5694\/mja2.51560","article-title":"Management of atopic dermatitis: a narrative review","volume":"216","author":"Goh","year":"2022","journal-title":"Med J Aust"},{"key":"2026031913332832200_ljaf482-B18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection","volume":"8","author":"Fishbein","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026031913332832200_ljaf482-B19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2026031913332832200_ljaf482-B20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"2026031913332832200_ljaf482-B21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nri.2017.114","article-title":"Neuroimmunology: JAK in the itch","volume":"17","author":"Bordon","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"2026031913332832200_ljaf482-B22","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/1346-8138.15090","article-title":"Clinical practice guidelines for the management of atopic dermatitis 2018","volume":"46","author":"Katoh","year":"2019","journal-title":"J Dermatol"},{"key":"2026031913332832200_ljaf482-B23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/exd.14753","article-title":"Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: a systematic review","volume":"32","author":"Sadeghi","year":"2023","journal-title":"Exp Dermatol"},{"key":"2026031913332832200_ljaf482-B24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/1744666X.2022.1993061","article-title":"Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis","volume":"18","author":"Fardos","year":"2022","journal-title":"Expert Rev Clin Immunol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf482\/65660634\/ljaf482.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/4\/629\/65660634\/ljaf482.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/4\/629\/65660634\/ljaf482.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:33:37Z","timestamp":1773941617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/4\/629\/8361728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,29]]},"published-print":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf482","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,11,29]]}}}